Polyrizon (PLRZ) said Thursday that its proprietary Nasarix nasal spray met all required biological safety standards in a biocompatibility evaluation program.
The testing followed internationally recognized standards and all key endpoints, including cytotoxicity, sensitization, irritation, and systemic toxicity, met acceptance criteria, the company said.
The completion of the program is an "important step toward potential commercialization of the product as a novel nasal barrier technology designed to help individuals suffering from seasonal allergies," the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments